Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level652 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,842 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04006821 | PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma | unknown | Phase 2 | 30 | China Medical University, ChinaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04982939 | Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer | unknown | Phase 2 | 210 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT05002686 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | unknown | Phase 2 / Phase 3 | 60 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04890392 | Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC | unknown | Phase 2 | 20 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT05000554 | The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer | unknown | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04973475 | Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer | unknown | Phase 2 | 180 | Fujian Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04948125 | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04934618 | A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer | unknown | Phase 2 | 85 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 2 | 35 | Zhou FuxiangOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04442984 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)(IRIGA) | unknown | Phase 2 | 326 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02901301 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | unknown | Phase 1 / Phase 2 | 41 | Yonsei UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826107 | Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer | unknown | Phase 2 | 196 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT04563975 | Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer | unknown | Phase 2 | 54 | Tao ZhangOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04797923 | A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination | unknown | Phase 2 | 43 | Gangnam Severance HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04792515 | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer(CCWSA/OAFLAG) | unknown | Phase 2 | 67 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04777162 | Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04781413 | Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer | unknown | Phase 1 / Phase 2 | 38 | Ruijin HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT03322969 | Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT01359397 | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer(B-DOCT) | unknown | Phase 2 | — | The Netherlands Cancer InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04136600 | EGFR Monoclonal Antibody for Advanced Gastric Cancer | unknown | Phase 2 | 100 | Shanghai Changzheng HospitalOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT03154983 | The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 48 | Zhou FuxiangOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT04631757 | Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | unknown | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT04567069 | Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment | unknown | Phase 1 / Phase 2 | 45 | The Second Hospital of Shandong UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04555304 | Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy | unknown | Phase 2 | 81 | Chengdu Kanghong Biotech Co., Ltd.INDUSTRY | 0 | Sep 18, 2020 | clinicaltrials |
| NCT04358341 | Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | unknown | Phase 2 | 136 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT04410887 | Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) | unknown | Phase 1 / Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jun 1, 2020 | clinicaltrials |
| NCT04367025 | Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer | unknown | Phase 2 | 70 | Chinese PLA General HospitalOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT04152889 | A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT04345770 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer | unknown | Phase 2 | 100 | Wuhan UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT04345783 | Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer | unknown | Phase 2 | 30 | Beijing Friendship HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT04286711 | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 52 | China Medical University, ChinaOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT04263870 | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(CTSCAPOXSEA) | unknown | Phase 2 | 36 | Sichuan UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04065282 | The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma. | unknown | Phase 2 | 36 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04258644 | Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | unknown | Phase 2 | 30 | Beijing Friendship HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT04258657 | Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer | unknown | Phase 2 | 20 | Beijing Friendship HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT03192735 | Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer | unknown | Phase 2 | 50 | Chang-Ming Huang, Prof.OTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03957564 | Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer | unknown | Phase 2 | 40 | Affiliated Hospital of Qinghai UniversityOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04202484 | Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | unknown | Phase 2 | 116 | Zhejiang Cancer HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04182724 | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 57 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04005365 | Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer | unknown | Phase 2 | 78 | Yijing HeOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02585908 | Safety and Efficacy of γδ T Cell Against Gastric Cancer | unknown | Phase 1 / Phase 2 | 120 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT04155671 | POF Versus FOLFOX Plus IP Paclitaxel in AGC | unknown | Phase 2 | 260 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 7, 2019 | clinicaltrials |
| NCT04149015 | Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 4, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Sep 30, 2021source: clinicaltrials